Becker's Healthcare November 30, 2022
Cancer Focus Fund, a venture capital arm of Houston-based University of Texas MD Anderson Cancer Center, has joined a $25 million series A funding round for Nectin Therapeutics, which develops novel immunotherapies.
The biotech company dosed its first patient in a phase 1 clinical trial Nov. 30 at MD Anderson to test NTX1088, a protein blocker targeting locally advanced and metastatic solid tumors.
“NTX1088’s triple mechanism of action...
Today's Sponsors
Today's Sponsor